1 | Nucleolin Is a Functional Binding Protein for Salinomycin in Neuroblastoma Stem Cells. (Wang F, Zhou S, Qi D, Xiang SH, Wong ET, Wang X, Fonkem E, Hsieh TC, Yang J, Kirmani B, Shabb JB, Wu JM, Wu M, Huang JH, Yu WH, Wu E) J Am Chem Soc 2019 Feb 27;141(8):3613-3622 33 Citations |
1 | Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. (Rosati R, Polin L, Ducker C, Li J, Bao X, Selvakumar D, Kim S, Xhabija B, Larsen M, McFall T, Huang Y, Kidder BL, Fribley A, Saxton J, Kakuta H, Shaw P, Ratnam M) Clin Cancer Res 2018 Dec 15;24(24):6509-6522 14 Citations |
1 | Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. (Wang Y, Xie Y, Li J, Peng ZH, Sheinin Y, Zhou J, Oupický D) ACS Nano 2017 Feb 28;11(2):2227-2238 391 Citations |
1 | The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. (Phan AT, Dave B) Cancer Med 2016 Oct;5(10):2953-2964 13 Citations |
1 | Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. (Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH) EBioMedicine 2016 Jun;8:117-131 72 Citations |
1 | Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. (Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA) PLoS One 2016;11(2):e0148730 15 Citations |
1 | Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. (Koprowski S, Sokolowski K, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M) J Surg Res 2015 Oct;198(2):434-40 25 Citations |
1 | Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. (Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL) Cancer Chemother Pharmacol 2014 Oct;74(4):831-8 20 Citations |
3 | Anticancer activity of VDR-coregulator inhibitor PS121912. (Sidhu PS, Teske K, Feleke B, Yuan NY, Guthrie ML, Fernstrum GB, Vyas ND, Han L, Preston J, Bogart JW, Silvaggi NR, Cook JM, Singh RK, Bikle DD, Arnold LA) Cancer Chemother Pharmacol 2014 Oct;74(4):787-98 19 Citations |
1 | Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. (Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S) Immunol Res 2014 Aug;59(1-3):188-202 46 Citations |
1 | Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. (Giri K, Shameer K, Zimmermann MT, Saha S, Chakraborty PK, Sharma A, Arvizo RR, Madden BJ, Mccormick DJ, Kocher JP, Bhattacharya R, Mukherjee P) Bioconjug Chem 2014 Jun 18;25(6):1078-90 74 Citations |
1 | CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. (Colbert LE, Petrova AV, Fisher SB, Pantazides BG, Madden MZ, Hardy CW, Warren MD, Pan Y, Nagaraju GP, Liu EA, Saka B, Hall WA, Shelton JW, Gandhi K, Pauly R, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS) Cancer Res 2014 May 15;74(10):2677-87 31 Citations |
1 | Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. (Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B) Int J Radiat Oncol Biol Phys 2012 Nov 15;84(4):e525-31 20 Citations |
1 | An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. (Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ) Cancer Cell 2011 Sep 13;20(3):384-99 93 Citations |
1 | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. (Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC) Blood 2011 Jun 09;117(23):6287-96 656 Citations |
1 | Salirasib in the treatment of pancreatic cancer. (Bustinza-Linares E, Kurzrock R, Tsimberidou AM) Future Oncol 2010 Jun;6(6):885-91 41 Citations |
2 | Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. (Veldkamp CT, Ziarek JJ, Peterson FC, Chen Y, Volkman BF) J Am Chem Soc 2010 Jun 02;132(21):7242-3 62 Citations |
1 | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. (Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW) Blood 2010 Jun 24;115(25):5232-40 193 Citations |
1 | Effects of pterostilbene on melanoma alone and in synergy with inositol hexaphosphate. (Schneider JG, Alosi JA, McDonald DE, McFadden DW) Am J Surg 2009 Nov;198(5):679-84 22 Citations |
1 | Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. (Symes JC, Kurin M, Fleshner NE, Medin JA) Mol Cancer Ther 2008 Sep;7(9):3018-28 21 Citations |
1 | Synthesis and characterization of BODIPY-labeled colchicine. (Arnold LA, Ranaivo P, Guy RK) Bioorg Med Chem Lett 2008 Nov 15;18(22):5867-70 7 Citations |
1 | Studies in target-based treatment. (Kurzrock R) Mol Cancer Ther 2007 May;6(5):1477 3 Citations |
1 | Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. (Li L, Ahmed B, Mehta K, Kurzrock R) Mol Cancer Ther 2007 Apr;6(4):1276-82 311 Citations |
1 | A preliminary study on antimetastatic activity of Thuja occidentalis L. in mice model. (Sunila ES, Kuttan G) Immunopharmacol Immunotoxicol 2006;28(2):269-80 37 Citations |
1 | Photophysical, photochemical, and tumor-selectivity properties of bromine derivatives of rhodamine-123. (Lacerda SH, Abraham B, Stringfellow TC, Indig GL) Photochem Photobiol 2005;81(6):1430-8 23 Citations |
1 | 1-Methyl-3-nitropyridine: an efficient oxidant of NADH in non-enzymatic and enzyme-mediated processes. (Wieczorkowska M, Zielonka J, Celińska J, Adamus J, Ciesielska E, Marcinek A, Szmigiero L, Gebicki J) Free Radic Res 2003 Nov;37(11):1157-62 7 Citations |
1 | Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. (Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA) Semin Oncol 2001 Jun;28(3 Suppl 10):25-33 57 Citations |
1 | Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. (Khoshyomn S, Manske GC, Lew SM, Wald SL, Penar PL) Pediatr Neurosurg 2000 Sep;33(3):123-31 36 Citations |
1 | Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. (Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD) Cancer Res 1995 Sep 01;55(17):3803-9 11 Citations |
1 | Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. (Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, Dimanche-Boitrel MT) Int J Cancer 1995 Jun 09;61(6):873-9 24 Citations |
1 | Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. (Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG) Cancer 1994 Oct 01;74(7):1891-8 24 Citations |
2 | Enhancement of merocyanine 540 uptake and photodynamic cell killing by salicylates. (Feix JB, Anderson MS, Kalyanaraman B) Cancer Res 1994 Jul 01;54(13):3474-8 4 Citations |